Telix Reports $204M Revenue, Up 63% YOY
Telix today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.
Gozellix Receives Permanent HCPCS Code
Telix today announces that its next-generation PSMA PET imaging agent, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code by the U.S. Centers for Medicare & Medicaid Services (CMS).
Telix at ANZSNM Annual Scientific Meeting 2025
Telix’s Illuccix PSMA-PET Imaging Agent Approved in France
Telix announces its Annual General Meeting of shareholders to be held at
AUA25: Telix to Showcase Urologic Pipeline at AUA: ProstACT Global, Illuccix® and Zircaix®
Join Telix this week at the 2025 The American Urological Association (AUA) Annual Meeting in Las Vegas, NV.
Telix Reports US$186M Q1 Revenue, Up 62% YOY
Telix announces its Annual General Meeting of shareholders to be held at
Notice of Annual General Meeting 2025
Telix announces its Annual General Meeting of shareholders to be held at
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
Telix today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study.
Telix Responds to Recent U.S. Government Actions
Telix advises that it does not expect any material impact on its business or supply chain as the result of the international trade tariffs levied by the U.S. government, announced on 2 April 2025.
Anne Whitaker Appointed as Non-Executive Director
Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 2025